Last updated: May 29, 2026
NURTEC ODT Suppliers: Who Manufactures Rimegepant and What Companies Provide Key Materials
Executive summary: Nurtec ODT (rimegepant) is manufactured and distributed through a defined, FDA-audited supply chain centered on the commercial drug substance (API) and drug product (tablet) manufacturing sites used for NDA supply. Public-facing “supplier” information is split across FDA manufacturing listings (Drug Master File or application manufacturing sites), Orange Book/label references to manufacturing, and secondary reporting by contract manufacturers. The supplier landscape is dominated by the NDA’s listed finished dosage form manufacturer(s), API manufacturer(s), and upstream excipient/packaging vendors bound by cGMP and quality agreements.
Who supplies Nurtec ODT (rimegepant) drug product manufacturing?
Featured snippet answer: The finished-dosage form suppliers for Nurtec ODT are the FDA-listed drug product manufacturing sites tied to the NDA for rimegepant ODT tablets, as shown in the product label and FDA manufacturing database.
What entities typically appear as Nurtec ODT drug product manufacturers
Nurtec ODT’s “suppliers” in regulatory terms generally break down into:
- Finished dosage form (FDF) manufacturer: ODT tablet manufacturing, including blending, compression, coating or matrix processing (as applicable), and final packaging.
- Batch release testing site: QC labs that test identity, assay, impurities, dissolution/ODT performance, and microbiological attributes.
- Secondary packaging and distribution site: Unit-dose packaging, bottle/strip packaging, and labeling.
How to map “supplier” to FDA listings
For Nurtec ODT, identify the supplier through:
- FDA label “Manufactured for” / “Manufactured by” sections
- FDA Drugs@FDA / label manufacturing section
- FDA product manufacturing site listings (NDA-associated facilities)
- Changes Being Effected / Prior Approval supplement manufacturing updates (when facilities change)
Who supplies the rimegepant API (drug substance) for Nurtec ODT?
Featured snippet answer: The API suppliers are the NDA-linked API manufacturing sites (often different legal entities than the finished-dosage form manufacturer) listed in FDA submissions and labeling.
Drug substance supplier structure
Rimegepant supply chains usually include:
- API synthesis site(s): one or more plants performing key steps (chemical synthesis, purification, drying).
- API quality-release testing: QC to confirm API critical quality attributes such as impurities profile and polymorphic form.
- Intermediates suppliers: upstream chemical intermediate manufacturers that may be shielded unless disclosed in FDA filings.
Where to confirm the API supplier
- NDA product label and FDA facility listings are the highest-confidence sources.
- Where only one API facility is disclosed publicly, secondary reporting may name additional potential API makers, but facility-level cGMP linkage must be validated via FDA databases or DMF/CMC references.
What excipient and packaging suppliers support Nurtec ODT tablets?
Featured snippet answer: Excipients and packaging suppliers are controlled under cGMP change control and supplier qualification; the names are typically not fully disclosed in public labels.
Typical ODT materials in Nurtec ODT (by function)
Without relying on non-public vendor names, ODT supplier categories include:
- Superdisintegrant (ODT disintegration performance)
- Binder/matrix-former (tablet integrity)
- Filler (bulk and compressibility)
- Lubricant (manufacturing flow and ejection)
- Sweetener and flavor (patient acceptability)
- Colorant (where applicable)
- Packaging components: desiccant, bottle/closures or blister materials, and labeling materials
How the vendor list becomes binding
In practice, ODT excipient and packaging supplier identity becomes binding via:
- Supplier qualification packages (CoA formats, impurity specs)
- Raw material change control under ICH Q7/Q9
- Stability protocols for both drug substance and packaged drug product
Which contract manufacturers produce Nurtec ODT tablets under the NDA?
Featured snippet answer: The contract manufacturers are the FDA-listed finished dosage form manufacturing sites for Nurtec ODT ODT tablets under the NDA.
What contract manufacturing roles exist
- Blending and compression of ODT tablet core
- ODT-specific granulation/process development alignment
- In-process controls aligned to dissolution and hardness/fragility specs
- Packaging line qualification (unit-dose protection, moisture sensitivity)
How to assess whether supply is single-site or multi-site
In supply-risk analysis, you map:
- Number of NDA-listed manufacturing facilities
- Whether multiple sites have released product historically
- Whether label changes indicate facility expansions
What suppliers support Nurtec ODT clinical trial supply and commercial supply?
Featured snippet answer: Clinical and commercial manufacturing may use the same or different facilities, but both are cGMP-qualified and tied to the NDA’s CMC history.
Common patterns
- Clinical phase: early commercial-like batches may come from a pilot plant or different line.
- Commercial phase: scaling typically locks to FDA-listed commercial manufacturing sites.
- Lifecycle CMC changes: later supplements add or swap manufacturing plants.
What is the Nurtec ODT supply chain risk profile (API vs drug product vs packaging)?
Featured snippet answer: The highest-risk nodes are typically API release and ODT packaging protection (moisture), since ODT performance is sensitive to environmental exposure and formulation excipient quality.
Risk dimensions used in pharma procurement
- Regulatory: FDA inspection history of the listed facilities
- Technical: API critical quality attributes and impurity control
- Operational: number of qualified manufacturing lines and packaging lines
- Logistics: lead times for specialty ODT excipients and packaging films/blisters
How does Nurtec ODT supplier structure compare with competing CGRP antagonists (e.g., Ubrelvy)?
Featured snippet answer: Competitive comparison is driven by who manufactures the API and which site(s) bottle/package finished product. Without a facility-by-facility dataset, supplier identity must be compared via the same FDA sources for each product.
What to compare
- API manufacturing sites count
- FDF site count
- Whether both drugs share common CMOs
- Any disclosed facility additions on labels over time
When do Nurtec ODT supplier changes show up in FDA filings and labels?
Featured snippet answer: Manufacturing site changes typically appear as:
- Updated labeling “Manufactured for/Manufactured by”
- FDA approval of CMC supplements
- Public facility listing updates
What “supplier change” means in practice
- A new drug product plant requires bridging studies or comparability under the approved CMC pathway.
- New API plants require validation of impurity profile consistency and process controls.
Key Takeaways
- “Nurtec ODT suppliers” maps to FDA-listed drug substance and drug product manufacturing sites tied to the NDA.
- The supply chain has three procurement-critical layers: API, finished ODT drug product manufacturing, and moisture-protective packaging.
- For a defensible supplier roster, use label manufacturing statements and FDA manufacturing facility listings as primary sources, then layer in excipient/packaging qualification under cGMP controls.
- Multi-site supply reduces discontinuity risk; supplier counts and facility transitions are visible through label and FDA CMC updates.
FAQs
- Where do I find the FDA-listed manufacturing sites for Nurtec ODT?
- Who makes the rimegepant API used in Nurtec ODT?
- Which excipients are critical for Nurtec ODT performance and how are suppliers qualified?
- How do Nurtec ODT manufacturing changes appear in updated product labels?
- What supply chain nodes pose the biggest risk for an ODT like Nurtec ODT?
References
(No sources were provided in the prompt; therefore no citations can be included.)
